Arcoxia Safety Can Be Addressed In Labeling, Merck Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck is working with international regulatory agencies on appropriate labeling changes to reflect cardiovascular safety issues that prompted withdrawal of Vioxx. Arcoxia's cardiovascular safety profile is strong for "short-term use," Merck says.